Item 2.02 Results of Operations and Financial Condition.
On November 10, 2021, Athira Pharma, Inc. (the "Company") issued a press release
reporting its financial results for the quarter ended September 30, 2021. A copy
of the press release is furnished herewith as Exhibit 99.1.
Item 7.01 Regulation FD Disclosure.
The Company announces material information to the public through a variety of
means, including filings with the Securities and Exchange Commission, press
releases, public conference calls, the Company's website (www.athira.com), its
investor relations website (investors.athira.com), and its news site
(investors.athira.com/news-and-events/press-releases). The Company uses these
channels, as well as social media, including its Twitter account
(@athirapharma), LinkedIn account (www.linkedin.com/company/athirapharma), and
Facebook page (www.facebook.com/athirapharmainc), to communicate with investors
and the public about the Company, its product candidates, and other matters.
Therefore, the Company encourages investors, the media, and others interested in
the Company to review the information it makes public in these locations, as
such information could be deemed to be material information.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Athira Pharma, Inc. press release dated November 10, 2021
104 Cover Page Interactive Data File (formatted as Inline XBRL)
The information furnished in this Current Report under Items 2.02 and 7.01 and
the exhibit attached hereto shall not be deemed "filed" for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses